Please assess the completion status of the following clinical trial:

Trial Title: Revefenacin in Chinese Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease(COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Key inclusion criteria include:~  * Males and females of Chinese ethnicity, at least 40 years of age. Females may be of either childbearing or non-childbearing potential. All females of childbearing potential must be using an acceptable, highly effective method of contraception and have a negative pregnancy test at screening.~ * A clinical diagnosis for at least 6 months prior to screening of COPD according to Global Initiative for Chronic Obstructive Lung Disease(GOLD) guidelines.~ * Subject is capable of performing reproducible spirometry maneuvers as described by current American Thoracic Society/European Respiratory Society (ATS/ERS) Guidelines and has a post-ipratropium (500 mcg nebulized) Forced Expiratory Volume in~    1 second(FEV1)/Forced Vital Capacity(FVC) ratio \<0.7 at Visit 2.~ * Subject has moderate to very severe COPD with a post-ipratropium (500 mcg nebulized) FEV1 less than 80% of predicted normal (using the Global Lung Function Initiative reference range; ) and an absolute FEV1 \>700 mL at Visit 2~ * Current smoker or ex-smoker, with a history of at least 10 pack-years of tobacco smoking. Ex-smokers must have stopped smoking \>6 months prior to Visit 1.~Exclusion Criteria:~* Key exclusion criteria include:~  * Previously dosed with Revefenacin.~ * Current diagnosis of asthma.~ * Alpha-1 anti-trypsin deficiency.~ * Other chronic or active respiratory disorder (e.g., clinically significant \[as determined by the Investigator\] bronchiectasis, pulmonary fibrosis, sarcoidosis, pneumoconiosis, active tuberculosis).~ * Symptoms of, or treatment for an Acute Exacerbation of COPD(AECOPD) requiring antibiotics and/or oral/systemic corticosteroids or in-patient hospitalization during the 28 days preceding screening or during the screening period between Visit 1 and Visit 3.~ * Pneumonia requiring hospitalization within 28 days prior to screening or during the screening period between Visit 1 and Visit 3.~ * Lower respiratory tract infection requiring treatment with antibiotics during the 28 days preceding screening or during the screening period between Visit 1 and Visit 3.~ * History or presence of pulmonary hypertension, respiratory failure, cor pulmonale or right ventricular failure which may impact the safety of the subject in the clinical judgement of the Investigator.~ * History of pulmonary lobectomy, lung volume reduction surgery, or lung transplantation.~ * Use of supplemental oxygen therapy for more than 15 hours per day (includes night-time use).~ * Subjects with hepatic impairment.~ * Subject suffers from any medical condition that would preclude the use of inhaled anticholinergics, including narrow-angle glaucoma, symptomatic benign prostatic hyperplasia, bladder neck obstruction, or urinary retention.~ * Subjects who are unable to stop any of the following medications, and refrain from their use throughout the study until the final dose of study drug:~    * Short-acting β2 agonists (except study-supplied salbutamol).~   * Short-acting anticholinergic agents (except those used for reversibility testing).~   * Long-acting anticholinergics (except study supplied medication).~   * Combination β2 agonists/anticholinergic agents.~   * Combination β2 agonists/inhaled corticosteroids/anticholinergic agents.~   * Phosphodiesterase 4 inhibitors.~   * Theophyllines.~   * Leukotriene inhibitors.~   * Orally inhaled nedocromil or cromolyn sodium.~   * Oral or parenteral corticosteroids.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Revefenacin inhalation solution 175 mcg QD. (Type: EXPERIMENTAL): Revefenacin inhalation solution 175 mcg QD.
- Placebo inhalation solution QD. (Type: PLACEBO_COMPARATOR): Placebo inhalation solution QD.

Based on this trial design, predict the completion outcome and termination type (if applicable).